Yabang Pharmaceutical

Yabang Pharmaceutical is a prominent Chinese pharmaceutical enterprise and a core subsidiary of the Yabang Investment Holding Group. The company specializes in the research, development, and large-scale production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms, with a particular emphasis on small molecule therapeutics. It is globally recognized as one of the largest manufacturers of antimalarial drugs, providing WHO-prequalified artemisinin-based combination therapies (ACTs) to international markets. Beyond its leadership in infectious diseases, Yabang maintains a diverse portfolio covering cardiovascular, gastrointestinal, and respiratory health. The company operates multiple state-of-the-art, GMP-certified manufacturing facilities in Jiangsu province, supporting its role as a key supplier to both domestic healthcare systems and global aid organizations.